The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
The future of epigenetic therapy in solid tumours—lessons from the past
Open accessAbstract
The promise of targeting epigenetic abnormalities for cancer therapy has not been realized for solid tumours, although increasing evidence is demonstrating its worth in haematological malignancies. In fact, true clinical efficacy in haematopoietic-related neoplasms has only become evident at low doses of epigenetic-targeting drugs (namely, inhibitors of histone deacetylase and DNA methyltransferases). Describing data from preclinical studies and early clinical trial results, we hypothesize that in using low-dose epigenetic-modulating agents, tumour cells can be reprogrammed, which overrides any immediate cytotoxic and off-target effect observed at high dose. We suggest that such optimization of drug dosing and scheduling of currently available agents could give these agents a prominent place in cancer management—when used alone or in combination with other therapies. If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 431
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Self-citationIdentification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Self-citationEpigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Self-citationA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA
Ooi, S. K. T., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., Lin, S.-P., Allis, C. D., et al. (2007) · Nature · doi:10.1038/nature05987 · Cited by 1,567
Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells
Lister, R., Pelizzola, M., Kida, Y. S., Hawkins, R. D., Nery, J. R., Hon, G., Antosiewicz-Bourget, J., O’Malley, R., Castanon, R., Klugman, S., et al. (2011) · Nature · doi:10.1038/nature09798 · Cited by 1,549
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.020 · Cited by 1,335
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226
Doi, A., Park, I.-H., Wen, B., Murakami, P., Aryee, M. J., Irizarry, R., Herb, B., Ladd-Acosta, C., Rho, J., Loewer, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.471 · Cited by 1,177
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130
Self-citationLineage Tracing Reveals Lgr5 + Stem Cell Activity in Mouse Intestinal Adenomas
Schepers, A. G., Snippert, H. J., Stange, D. E., van den Born, M., van Es, J. H., van de Wetering, M., & Clevers, H. (2012) · Science · doi:10.1126/science.1224676 · Cited by 1,072
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
Ligtenberg, M. J. L., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., Lee, T. Y. H., Bodmer, D., Hoenselaar, E., Hendriks-Cornelissen, S. J. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.283 · Cited by 818
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Defining the mode of tumour growth by clonal analysis
Driessens, G., Beck, B., Caauwe, A., Simons, B. D., & Blanpain, C. (2012) · Nature · doi:10.1038/nature11344 · Cited by 717
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citationKantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685
SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis
Vaquero, A., Scher, M. B., Lee, D. H., Sutton, A., Cheng, H.-L., Alt, F. W., Serrano, L., Sternglanz, R., & Reinberg, D. (2006) · Genes & Development · doi:10.1101/gad.1412706 · Cited by 665
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Tsai, H.-C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 650
Self-citationThe role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glöckner, S., Piantadosi, S., Gabrielson, E., Pridham, G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706550 · Cited by 593
Self-citationEpigenetic reprogramming and induced pluripotency
Hochedlinger, K., & Plath, K. (2009) · Development · doi:10.1242/dev.020867 · Cited by 553
The Human Histone Deacetylase Family
Gray, S. G., & Ekström, T. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5080 · Cited by 546
van der Vlag, J., & Otte, A. P. (1999) · Nature Genetics · doi:10.1038/70602 · Cited by 527
Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine.
Santi, D. V., Norment, A., & Garrett, C. E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.22.6993 · Cited by 518
FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension
Kaminskas, E., Farrell, A. T., Wang, Y.-C., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-176 · Cited by 490
Solomon, J. M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P. S., & Huber, L. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.28-38.2006 · Cited by 486
Germline epimutation of MLH1 in individuals with multiple cancers
Suter, C. M., Martin, D. I. K., & Ward, R. L. (2004) · Nature Genetics · doi:10.1038/ng1342 · Cited by 475
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S.-L., Leighton, J. K., Patel, H., Rahman, A., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2135 · Cited by 423
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation
Pruitt, K., Zinn, R. L., Ohm, J. E., McGarvey, K. M., Kang, S.-H. L., Watkins, D. N., Herman, J. G., & Baylin, S. B. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020040 · Cited by 387
Self-citationO'Hagan, H. M., Mohammad, H. P., & Baylin, S. B. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000155 · Cited by 386
Self-citationMolecules that Promote or Enhance Reprogramming of Somatic Cells to Induced Pluripotent Stem Cells
Feng, B., Ng, J.-H., Heng, J.-C. D., & Ng, H.-H. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.005 · Cited by 381
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Thol, F., Damm, F., Lüdeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Göhring, G., Schlegelberger, B., Hoelzer, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4894 · Cited by 374
Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
Chung, C.-W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200108t · Cited by 334
Nonoverlapping Functions of the Polycomb Group Cbx Family of Proteins in Embryonic Stem Cells
Morey, L., Pascual, G., Cozzuto, L., Roma, G., Wutz, A., Benitah, S. A., & Di Croce, L. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.12.006 · Cited by 328
Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer
Chan, T. L., Yuen, S. T., Kong, C. K., Chan, Y. W., Chan, A. S., Ng, W. F., Tsui, W. Y., Lo, M. W., Tam, W. Y., Li, V. S., et al. (2006) · Nature Genetics · doi:10.1038/ng1866 · Cited by 324
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
A DNA hypermethylation module for the stem/progenitor cell signature of cancer
Easwaran, H., Johnstone, S. E., Van Neste, L., Ohm, J., Mosbruger, T., Wang, Q., Aryee, M. J., Joyce, P., Ahuja, N., Weisenberger, D., et al. (2012) · Genome Research · doi:10.1101/gr.131169.111 · Cited by 292
Self-citationMolecular Coupling of DNA Methylation and Histone Methylation
Hashimoto, H., Vertino, P. M., & Cheng, X. (2010) · Epigenomics · doi:10.2217/epi.10.44 · Cited by 286
DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival
De Carvalho, D. D., Sharma, S., You, J. S., Su, S.-F., Taberlay, P. C., Kelly, T. K., Yang, X., Liang, G., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.045 · Cited by 285
Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
Metzeler, K. H., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Becker, H., Curfman, J., Holland, K. B., Schwind, S., Whitman, S. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7742 · Cited by 280
Ecker, J. R., Bickmore, W. A., Barroso, I., Pritchard, J. K., Gilad, Y., & Segal, E. (2012) · Nature · doi:10.1038/489052a · Cited by 277
Metzeler, K. H., Becker, H., Maharry, K., Radmacher, M. D., Kohlschmidt, J., Mrózek, K., Nicolet, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-368225 · Cited by 275
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
EZH2 mutational status predicts poor survival in myelofibrosis
Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A. V., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363424 · Cited by 262
Garcia-Manero, G., Gore, S. D., Cogle, C., Ward, R., Shi, T., MacBeth, K. J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4226 · Cited by 252
Mutant BRAF Melanomas—Dependence and Resistance
Poulikakos, P. I., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250
Resistance to BRAF Inhibition in Melanomas
Solit, D. B., & Rosen, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmcibr1013704 · Cited by 243
Abdel-Wahab, O., Pardanani, A., Patel, J., Wadleigh, M., Lasho, T., Heguy, A., Beran, M., Gilliland, D. G., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.58 · Cited by 231
Yeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Boyer, M., Mo, F. K. F., Koh, J., Rha, S. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2395 · Cited by 199
Witta, S. E., Jotte, R. M., Konduri, K., Neubauer, M. A., Spira, A. I., Ruxer, R. L., Varella-Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 196
Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G., List, A. F., Gore, S. D., & Seymour, J. F. (2011) · Cancer · doi:10.1002/cncr.25774 · Cited by 194
Giaccone, G., Rajan, A., Berman, A., Kelly, R. J., Szabo, E., Lopez-Chavez, A., Trepel, J., Lee, M.-J., Cao, L., Espinoza-Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4467 · Cited by 189
Fu, S., Hu, W., Iyer, R., Kavanagh, J. J., Coleman, R. L., Levenback, C. F., Sood, A. K., Wolf, J. K., Gershenson, D. M., Markman, M., et al. (2011) · Cancer · doi:10.1002/cncr.25701 · Cited by 183
Tefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. (2012) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 172
The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors
Spannhoff, A., Hauser, A., Heinke, R., Sippl, W., & Jung, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200900301 · Cited by 171
Genetic syndromes caused by mutations in epigenetic genes
Berdasco, M., & Esteller, M. (2013) · Human Genetics · doi:10.1007/s00439-013-1271-x · Cited by 163
MacKay, H. J., Hirte, H. W., Colgan, T. J., Covens, A., MacAlpine, K., Grenci, P., Wang, L. E., Mason, J., Pham, P.-A., Tsao, M., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.047 · Cited by 160
Bhatla, T., Wang, J., Morrison, D. J., Raetz, E. A., Burke, M. J., Brown, P. A., & Carroll, W. L. (2012) · Blood · doi:10.1182/blood-2012-01-401687 · Cited by 158
Kachhap, S. K., Rosmus, N., Collis, S. J., Kortenhorst, M. S. Q., Wissing, M. D., Hedayati, M. A., Shabbeer, S., Mendonca, J., Deangelis, J., Marchionni, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011208 · Cited by 154
Robert, C., & Rassool, F. V. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00003-3 · Cited by 153
Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
Astsaturov, I. A., Ratushny, V., Sukhanova, A. L., Einarson, M. B., Bagnyukova, T., Zhou, Y., Devarajan, K., Silverman, J. S., Tikhmyanova, N., Skobeleva, N., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2001083 · Cited by 148
Ferguson, A. T., Vertino, P. M., Spitzner, J. R., Baylin, S. B., Muller, M. T., & Davidson, N. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32260 · Cited by 146
Self-citationEffect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice.
Šorm, F., & Veselý, J. (1968) · PubMed · Cited by 134
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 126
IWAMOTO, F. M., Lamborn, K. R., Kuhn, J. G., Wen, P. Y., Yung, W. K. A., Gilbert, M. R., Chang, S. M., Lieberman, F. S., Prados, M. D., & Fine, H. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor017 · Cited by 126
DNA methylation and epigenetic mechanisms
Holliday, R. (1989) · Cell Biophysics · doi:10.1007/bf02991575 · Cited by 99
Gabbara, S., & Bhagwat, A. S. (1995) · Biochemical Journal · doi:10.1042/bj3070087 · Cited by 94
Hainsworth, J. D., Infante, J. R., Spigel, D. R., Arrowsmith, E. R., Boccia, R. V., & Burris, H. A. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.590568 · Cited by 92
Issa, J. J. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0355 · Cited by 91
hSirT1-Dependent Regulation of the PCAF-E2F1-p73 Apoptotic Pathway in Response to DNA Damage
Pediconi, N., Guerrieri, F., Vossio, S., Bruno, T., Belloni, L., Schinzari, V., Scisciani, C., Fanciulli, M., & Levrero, M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00552-08 · Cited by 88
Hypomethylating Therapy in an Aggressive Stroma-Rich Model of Pancreatic Carcinoma
Shakya, R., Gonda, T. A., Quante, M., Salas, M. C., Kim, S., Brooks, J. M., Hirsch, S., Davies, J. I., Cullo, A., Olive, K. P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1880 · Cited by 85
Epigenetic cancer therapy: Proof of concept and remaining challenges
Mund, C., & Lyko, F. (2010) · BioEssays · doi:10.1002/bies.201000061 · Cited by 85
Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
Meng, F., Sun, G., Zhong, M., Yu, Y., & BREWER, M. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.10 · Cited by 77
Isozaki, Y., Hoshino, I., Nohata, N., Kinoshita, T., Akutsu, Y., Hanari, N., Mori, M., Yoneyama, Y., Akanuma, N., Takeshita, N., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1537 · Cited by 76
Resolving the stem-cell debate
Gilbertson, R. J., & Graham, T. A. (2012) · Nature · doi:10.1038/nature11480 · Cited by 72
Girard, N., Jacoulet, P., Gainet-Brun, M., Elleuch, R., Pernet, D., Depierre, A., Dalphin, J., & Westeel, V. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181bbf223 · Cited by 72
Sulai, N. H., Jimma, T., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., Pardanani, A. D., & Tefferi, A. (2011) · Blood · doi:10.1182/blood.v118.21.1751.1751 · Cited by 61
Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells
Shin, H., Lee, Y. S., & Lee, Y. C. (2011) · Oncology Reports · doi:10.3892/or.2011.1585 · Cited by 50
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
Humeniuk, R., Menon, L. G., Mishra, P. J., Gorlick, R., Sowers, R., Rode, W., Pizzorno, G., Cheng, Y.-C., Kemeny, N., Bertino, J. R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0716 · Cited by 50
Yardley, D. A., Ismail-Khan, R. R., & Klein, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.27_suppl.268 · Cited by 24
Promises and challenges of anticancer drugs that target the epigenome
Verbrugge, I., Johnstone, R. W., & Bots, M. L. (2011) · Epigenomics · doi:10.2217/epi.11.82 · Cited by 23
Emerging Role of Epigenetic Therapy: Focus on Decitabine
Issa, J. J., & Kantarjian, H. M. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.05.003 · Cited by 11
Cited by
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Self-citationGene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199
“…clinical trials have been initiated to investigate the possibility of extending their utilization to solid tumors, such as ovarian and lung cancers, either alone or in combination with other drugs (Azad et al., 2013; Juergens et al., 2011; Li et al., 2014; Matei et al., 2012;Wrangle et al., 2013).”
BackgroundInfluentialTargeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Self-citationThe roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Metadata
- Authors
- Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-04-02
- Volume
- 10
- Issue
- 5
- Pages
- 256-266
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2000156285
- Cited by
- 335
- References
- 122
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.